secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001628280-23-009762
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical Q4 revenue $19.3M, up 26% YoY; net loss narrows to $2.4M; guides FY2023 sales $78-82M
--------------------------------------------------------------------------------

- Q4 2022 revenue $19.3M (+26% YoY); full-year revenue $72.8M (+17.6% YoY), highest ever.
- Net loss Q4 $2.4M ($0.20/share) vs $8.9M ($1.05) in Q4 2021; full-year net loss $18.7M ($1.89) vs $32.7M ($3.83).
- Debt reduced to $10.0M at year-end from $21.6M at end of 2021; cash used in ops improved to $17.4M from $33.5M.
- 2023 guidance: net sales $78-82M, gross profit $7-9M; focus on hemodialysis concentrates growth and profitability.
- Reacquired distribution rights from Baxter for >700 hemodialysis customers; new CEO Mark Strobeck joined July 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000162828023009762/0001628280-23-009762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000162828023009762/rmti-20230330.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-009762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer